Pharma BD Deal Intelligence
Pfizer entered an exclusive global license agreement with Nona Biosciences (a wholly owned subsidiary of Harbour BioMed) for HBM9033, an investigational MSLN-targeted antibody-drug conjugate for solid tumors, announced December 14, 2023. Nona received $53M upfront and near-term payments, up to $1.05B in development/commercial milestones, plus tiered royalties ranging from high single digits to high teens. Since the deal, Pfizer has advanced the asset (now also designated PF-08052666 / SGN-MesoC2, or "MesoC2") into the clinic: the Phase 1 open-label dose-escalation/expansion study NCT06466187 (sponsored by Seagen, a wholly owned Pfizer subsidiary) began August 2, 2024 in advanced solid tumors including mesothelioma, platinum-resistant ovarian cancer, pancreatic ductal adenocarcinoma, NSCLC, endometrial cancer and colorectal cancer, enrolling up to ~365 patients. Pfizer presented the Phase 1 study design at ASCO 2025 (poster TPS3163, June 2, 2025) and preclinical data on the TOP1i-based MSLN ADC at AACR 2025; the trial was active (not recruiting) as of mid-2026.